| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Bernards Rene is a Director at LIXT. Recent filings cover 5 purchases and 0 sales.
Our model assigns Bernards Rene a below-average insider score of 34/100, based on 5 past trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -45.8%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 3, 2023 | LIXT Lixte Biotechnology Holdings, Inc. | Director | Buy | 10,000 | $2.41 | $24,115.94 | -100% | -16.4% | -31.0% | |
| Dec 15, 2022 | LIXT Lixte Biotechnology Holdings, Inc. | Director | Buy | 15,000 | $0.51 | $7,650.00 | +11.1% | +26.2% | -61.0% | |
| Dec 12, 2022 | LIXT Lixte Biotechnology Holdings, Inc. | Director | Buy | 10,000 | $0.61 | $6,100.00 | +8.0% | +16.9% | -65.7% | |
| Nov 14, 2022 | LIXT Lixte Biotechnology Holdings, Inc. | Director | Buy | 52,500 | $0.53 | $27,825.00 | +72.4% | +91.1% | -47.0% |